trial

A Study of RO4917838 in Patients With Sub-optimally Controlled Symptoms of Schizophrenia (NN25307)

NCTId NCT01235520
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Completed
Enrollment 595 (actual)
Sponsored by Hoffmann-La Roche
Primary completion 2014-07
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Completed
Enrollment
595 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2011-01
Primary completion
2014-07
Eligibility
ALL · 18 Years

Interventions & indications

Drugs
RO4917838

Sponsors

Hoffmann-La RocheLead Sponsor

Sites

0 total

Linked catalysts

1
A Study of RO4917838 in Patients With Sub-optimally Controlled Symptoms of Schiz — primary completion2014-07

Facts & assertions

4 sourced
Enrollment
595
Phase
PHASE3
Primary Completion Date
2014-07
Status
COMPLETED
relationships
The graph out of here
drug
RO4917838
drug
lead_sponsor
Hoffmann-La Roche
company
indication
Schizophrenia
indication
Schizophrenia
indication